Colorado inmates reach a deal for access to hepatitis C drugs

first_imgPharmalot Colorado inmates reach a deal for access to hepatitis C drugs Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. First 30 days free. GET STARTED APStock After more than a year of bickering, Colorado officials have settled a lawsuit with prisoners that accused the state of failing to provide sufficient access to hepatitis C treatments. And in doing so, Colorado may effectively become the first state in the U.S. to provide care to all chronically infected inmates.The deal is the second such settlement among several class-action lawsuits filed against state prison systems around the country over access to the pricey medicines. A lawsuit was settled earlier this year with Massachusetts officials, while others are pending in five other states — Indiana, Minnesota, Missouri, Pennsylvania, and Tennessee. [email protected] Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. GET STARTED Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. By Ed Silverman Sept. 13, 2018 Reprintscenter_img What’s included? STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Log In | Learn More Ed Silverman What is it? Tags drug pricingpharmaceuticalsSTAT+ @Pharmalot About the Author Reprintslast_img read more